Clinical Trials Should Include Finding Maintenance Dose, FDA’s Temple Says
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER medical policy director says more thorough dose-response work would help reduce drug failure rate, and commends J&J for its study of Risperdal dosing.
You may also be interested in...
Agency Will Fund Research On Development Roadblocks; Orphan Drug Grants Are Model
FDA is going to fund research projects aimed at eliminating barriers to product development as part of its "critical path" initiative
Able Unable To Reform On Its Own? Firm Seeks Consent Decree To Address Manufacturing Issues
“We are prepared to enter discussions toward a decree at FDA’s earliest convenience,” Able says in letter to FDA. Company is pursuing consent decree instead of responding to FDA Form 483 report citing manufacturing deficiencies. The letter follows CEO Maury’s resignation the previous day.
Astellas Ends Aczone Acne Treatment Collaboration Agreement With QLT
QLT now has worldwide marketing rights to the topical acne treatment. Astellas believes labeling proposed by FDA will limit the market profile for Aczone, the company said. Aczone’s user fee deadline is July 7.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: